Nerviano, September 20, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A. and a clinical stage biotech, discovering and developing innovative therapies for the treatment of cancer, today announces the publication of preclinical data on NMS-P945 (link to article), its novel protease-cleavable thienoduocarmycin derivative payload-linker, with DNA damaging properties, in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
The manuscript describes preclinical studies on NMS-P945 conjugated to trastuzumab as biological proof-of-concept for the novel NMS payload-linker. Published data now show that NMS-P945, has superior physicochemical features for ADC production compared to other duocarmycin based payload-linkers. Trastuzumab-NMS-P945 ADC is highly active in vitro and in vivo with “bystander effect“ to be active in heterogeneous tumors, triggering features potentiating tumor cell recognition by the immune system and with potent activity in chemoresistant tumors. As a result of the reported features, NMS-P945 represents a highly effective, innovative, DNA damaging payload-linker for the creation of novel, next generation ADCs. Hugues Dolgos, PharmD, Chief Executive Officer of NMS S.r.l. and NMS Group S.p.A. commented “I am excited about our first peer reviewed publication of NMS-P945, our first innovative payload designed to enhance ADC efficacy versus products armed with MMAE and deruxtecan payloads. I am convinced that this publication will accelerate the initiation of novel projects in partnership with biotech and pharma worldwide”.